MRC-University of Glasgow Centre for Virus Research

Human papillomavirus (HPV) is one of the most common sexually transmitted infections, and while most of the time the virus is cleared naturally by the immune system, persistent infection can sometimes lead to cervical cancer. Cervical screening programmes are designed to catch early warning signs and prevent cancer from developing. However, at the MRC-University of Glasgow Centre for Virus Research (CVR), we are working to make this process even more effective. 

Currently, screening tests detect the presence of HPV and early cervical cell changes, helping healthcare professionals decide when treatment is necessary. However, not everyone who tests positive for HPV will go on to develop cancer, leading to potential overdiagnosis. Our research aims to address this challenge by identifying new molecular markers that change as cervical disease progresses—offering a more precise way to assess risk. 

One of the key tools in this research is digital PCR, a highly sensitive technique that allows us to detect these markers at very low levels. By integrating this technology into cervical screening, we hope to improve test accuracy. 

Another important focus of our work is self-sampling. Many women find it difficult to attend cervical screening appointments due to personal, cultural, or logistical reasons. By enabling women to collect their own samples at home, we hope to make screening more accessible and encourage higher participation in prevention programmes. 

More accurate and accessible screening could significantly reduce the stress associated with cervical testing, as well as reduce unnecessary procedures—ultimately benefiting both individuals and healthcare systems like the NHS. 

On HPV Awareness Day, we’re proud to highlight the ongoing research at the CVR that aims to enhance cervical cancer prevention and improve health outcomes for women. 

---

First published: 4 March 2025